Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Activation Of Natural Killer Cells By Soypeptide Lunasin and Cytokine: Implication In Cancer Immunotherapy For Lymphoma

Chun-Yu Tung, DVM, MS, Sharifah Kyazike, David Lewis, BA, MS, Ling Han, Alexander Kolb, MS, David Pelloso, Anthony Sinn, Karen E. Pollok, PhD, Shivani Srivastava, MD, Michael J. Robertson, MD, Hua-Chen Chang, PhD

Blood (2013) 122 (21): 1042.

https://doi.org/10.1182/blood.V122.21.1042.1042

Published: 2013

Journal Articles

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Bastian von Tresckow, MD, Aleksander Skotnicki, MD, PhD, Igur Lisukov, MD, Shivani Srivastava, MD, David S. Morgan, MD, Franck Morschhauser, MD, PhD, Caterina Stelitano, Jeffrey Szer, BMedSc, MBBS, FRACP, Dennis A. Eichenauer, MD, Jeremy S. Abramson, MD, Anna Sureda, MD, PhD, Christophe Ferme, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4648.

https://doi.org/10.1182/blood.V122.21.4648.4648

Published: 2013

Journal Articles

Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG)

Shivani Srivastava, MD, Hailin Feng, Menggang Yu, PhD, David Pelloso, Michael Robertson, MD

Blood (2010) 116 (21): 2780.

https://doi.org/10.1182/blood.V116.21.2780.2780

Published: 2010

Journal Articles

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

Rafat Abonour, Hayley Knollman, Attaya Suvannasankha, MD, Menggang Yu, Rebecca Britton, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Michael Robertson, MD, Kenneth Cornetta, MD, Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 1224.

https://doi.org/10.1182/blood.V114.22.1224.1224

Published: 2009

Journal Articles

A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.

Sherif Farag, MD, PhD, Lisa L Wood, RN, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Elizabeth Cox, Rafat Abonour, MD, Michael Robertson, MD,

Blood (2009) 114 (22): 3402.

https://doi.org/10.1182/blood.V114.22.3402.3402

Published: 2009

Journal Articles

Enhancing Natural Killer (NK) Cell Mediated Killing of Non-Hodgkin's Lymphoma.

Shivani Srivastava, MD, Hailin Feng, Shuhong Zhang, PhD, Jing Liang, Patrick Squiban, MD, Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 2706.

https://doi.org/10.1182/blood.V114.22.2706.2706

Published: 2009

Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 3870.

https://doi.org/10.1182/blood.V114.22.3870.3870

Published: 2009

Journal Articles

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

Sherif Farag, MD, PhD, Lisa L Wood, RN, Jennifer E. Schwartz, MD, FRCP(C), Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Michael Robertson, MD, Rafat Abonour, MD, Hamid Sayar, MD, Larry D. Cripe, MD

Blood (2009) 114 (22): 198.

https://doi.org/10.1182/blood.V114.22.198.198

Published: 2009

Journal Articles

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Aleah Smith, BS, Maria Berg, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1786.

https://doi.org/10.1182/blood.V110.11.1786.1786

Published: 2007

Journal Articles

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Maria Berg, BS, Aleah Smith, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1789.

https://doi.org/10.1182/blood.V110.11.1789.1789

Published: 2007

Journal Articles

Cyclosporine A (CSA) Significantly Reduces the Cytotoxic Effects of In Vitro Expanded NK Cells: Implications for Adoptive NK Cell Therapy in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (HCT).

Hisayuki Yokoyama, MD, PhD, Maria Berg, Andreas Lundqvist, PhD, J. Philip McCoy, PhD, Shivani Srivastava, MD, Aleah Smith, Richard Childs, MD

Blood (2007) 110 (11): 4899.

https://doi.org/10.1182/blood.V110.11.4899.4899

Published: 2007

Journal Articles

Adoptive Infusion of Alloreactive Donor NK Cells Reduces GVHD, Mediates Anti-Tumor Effects and Prolongs Survival in Recipients of MHC-Matched Hematopoietic Cell Transplantation.

Andreas Lundqvist, PhD, Philip McCoy, PhD, Leigh Samsel, MS, Aleah Smith, MS, Shivani Srivastava, MD, Nanae Harashima, PhD, Hisayuki Yokoyama, PhD, Maria Berg, MS, Richard Childs, MD

Blood (2006) 108 (11): 3233.

https://doi.org/10.1182/blood.V108.11.3233.3233

Published: 2006

Journal Articles

In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib.

Andreas Lundqvist, PhD, Kristy Greeneltch, PhD, Maria Berg, MS, Shivani Srivastava, MD, Nanae Harashima, PhD, Hisayuki Yokoyama, PhD, Aleah Smith, MS, Scott Abrams, PhD, Richard Childs, MD

Blood (2006) 108 (11): 925.

https://doi.org/10.1182/blood.V108.11.925.925

Published: 2006

NARROW

Activation Of Natural Killer Cells By Soypeptide Lunasin and Cytokine: Implication In Cancer Immunotherapy For Lymphoma

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG)

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.

Enhancing Natural Killer (NK) Cell Mediated Killing of Non-Hodgkin's Lymphoma.

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Cyclosporine A (CSA) Significantly Reduces the Cytotoxic Effects of In Vitro Expanded NK Cells: Implications for Adoptive NK Cell Therapy in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (HCT).

Adoptive Infusion of Alloreactive Donor NK Cells Reduces GVHD, Mediates Anti-Tumor Effects and Prolongs Survival in Recipients of MHC-Matched Hematopoietic Cell Transplantation.

In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only